KROS Jean Jacques Bienaime bought Keros Therapeutics, Inc. shares — SEC Form 4BUYKeros Therapeutics, Inc.

KROS is trading at $11.27, down 48.04% over the last 90 days and 35.71% over the last 30 days, placing it 50.02% below its 52-week high of $22.55.

• •The company is advancing rinvatercept phase II plans for DMD and ALS studies expected in 2026 (May 22 news).
• •Upcoming catalysts include the start of a DMD study and ALS regulatory talks, which could reshape investor sentiment (Apr 20 news).
• •The largest insider purchase in the company's history occurred on March 9, 2026, signaling potential confidence in the turnaround narrative (Signal Flags).

• •Short interest remains elevated at 9.91% of the float, potentially fueling volatility if the stock fails to rebound.
• •Analysts recently cut the price target to $21.20 following a Q1 miss where revenues plunged 93.01% (May 17, May 14 news).